Skip to main content

Table 1 Cure ratesa in studies for female and male patients with stress urinary incontinence

From: Can incontinence be cured? A systematic review of cure rates

Follow-up

3 m

6 m

12 m

18 m

2 y

3 y

5 y

Treatment – WOMEN

TVT

78%

50%

53%; 90.1% W

  

89.5%

81% W

92%

TVT-O

  

82.3%; 94.1%; 92.3%; 76%; 88.4% W; 88.8%

 

92.6%

86.4%; 87%

72%

74%

TVT Surgery/Individually tailored/MiniTape/SPARC

83.1% W (Primus)

27.7% W (North)

85%; 82% (VL)

 

31.6% W (North)

  

82.3% W (Primus)

32.3% W (North)

84.4% W (Primus)

TOT

82.8%

84.3%

63.4%; 74%; 88.6%; 93.3%

  

65%

 

Retropubic TVT

 

89.7%

86.1%; 65.5%; 81%

80.1%

77.4%

  

Sling

94.1%

92.2% W; 81.3%

81.2%; 90.8%; 90.1% W; 63.7%; 90.2%; 92.2%; 41%

52.8%

83.7%; 50.5%

  

89.8%; 81%; 44%

Colposuspension

 

22%/32%

    

90% W

28%/36%

Other (surgery)

  

79%

    

PFMT – supervised

52.9%; 5%

 

58.8%

    

Vaginal cone therapy

9%

      

Lifestyle advice – unsupervised

8%

      

Injectable bulking agents

  

36.9%; 24.8%

    

Duloxetine

NR

      

Treatment – MEN

Male sling

80%

55.8% W

58% W; 51.4% W; 53.8%

42.5%

48% W; 54% W

40% W; 53%

 

PFMT – supervised

51.9%

78%

     

PFMT – unsupervised

  

NR

    

PFMT – supervised + drug

78%

62%

     
  1. aCure defined as ‘cure’, ‘objective cure’, or ‘success (dry)’
  2. BI behavioral interventions; NR not reported; PFMT pelvic floor muscle training; TOT transobturator tape; TVT tension-free vaginal tape; TVT–O tension-free vaginal tape–obturator; W with containment products; VL Van Leijsen 2013; North North 2010; Primus Primus 2006